You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 6,565,844


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,565,844
Title: Protein production and protein delivery
Abstract:The present invention relates to DNA constructs that alter the expression of a targeted gene in a cell when the DNA construct is homologously recombined with a target site within the chromosomal DNA of the cell, as well as to a cell into which has been incorporated a new transcription unit containing an exogenous regulatory sequence operatively linked to an endogenous gene of the cell\'s chromosomal DNA. These constructs and cells can be used in a method of altering expression of the targeted gene.
Inventor(s): Treco; Douglas (Arlington, MA), Heartlein; Michael W. (Boxborough, MA), Selden; Richard F (Wellesley, MA)
Assignee: Transkaryotic Therapies, Inc. (Cambridge, MA)
Application Number:09/312,245
Patent Claims:1. A method of altering the expression of a targeted gene in a cell, the method comprising the steps of: (a) providing a DNA construct comprising: (i) a targeting sequence; (ii) an exogenous regulatory sequence; (iii) an exon; and (iv) an unpaired splice-donor site at the 3' end of the exon, (b) providing a cell, the genome of which comprises (i) a target site homologous to the targeting sequence, and; (ii) a targeted gene having an endogenous regulatory region; c) transfecting the cell with the DNA construct in vitro, thereby producing a transfected cell; d) maintaining the transfected cell under conditions appropriate for homologous recombination, thereby producing a homologously recombinant cell, the genome of which comprises the exogenous regulatory sequence, the construct-derived exon, and the construct-derived splice-donor site, in addition to all endogenous exons of the targeted gene; and e) maintaining the homologously recombinant cell under conditions appropriate for transcription under the control of the exogenous regulatory sequence, to produce a transcript of the construct-derived exon, the targeted gene, and any sequence lying between the construct-derived exon and the targeted gene, wherein the RNA of the transcript corresponding to the construct-derived splice-donor site directs splicing to a splice-acceptor site in the transcript which corresponds to a site within the targeted gene.

2. The method of claim 1 further comprising the steps of: (f) maintaining the homologously recombinant cell under conditions appropriate for splicing and translation of the transcript; and (g) confirming that a translation product of the spliced transcript was produced.

3. A cultured vertebrate cell into the genome of which is incorporated transcription unit, wherein the transcription unit comprises an exogenous regulatory sequence, an exogenous exon, and a splice-donor site at the 3' end of the exogenous exon, all located upstream of the endogenous transcription initiation site of an endogenous gene, the splice-donor site being operatively linked to the endogenous splice-acceptor site of the second endogenous exon of the endogenous gene.

4. The cultured vertebrate cell of claim 3, wherein the cell is selected from the group consisting of: HT1080 cells, HeLa cells, MCF-7 breast cancer cells, K-562 leukemia cells, KB carcinoma cells, 2780AD ovarian carcinoma cells, chinese hamster ovary (CHO) cells, and mouse L cells.

5. A cultured cell having incorporated therein a new transcription unit, wherein the new transcription unit comprises an exogenous inducible promoter operatively linked to an endogenous gene in the chromosomal DNA of the cell, provided that the exogenous inducible promoter is not identical to the endogenous promoter of the endogenous gene, and wherein the cell is selected from the group consisting of HT1080 cells, MCF-7 breast cancer cells, K-562 leukemia cells, KB carcinoma cells, 2780AD ovarian carcinoma cells, Chinese hamster ovary (CHO) cells, and mouse L cells.

6. A method of providing a protein to a mammal, comprising introducing into the mammal a homologoudsly recombinant cell which produces the protein, the homologously recombinant cell being generated by an in vitro process comprising: (a) providing a DNA construct comprising: (1) a targeting sequence, (2) an exogenous regulatory sequence, (3) an exon, and (4) an unpaired splice-donor site at the 3' end of the exon (b) providing a vertebrate cell, the genome of which comprises; (i) a target site homologous to the targeting sequence, and (ii) a targeted endogenous gene having an endogenous regulatory region; (c) transfecting the vertebrate cell with the DNA construct, thereby producing a transfected cell; (d) maintaining the transfected cell under conditions appropriate for homologous recombination, thereby producing a homologously recombinant cell the genome of which comprises the exogenous regulatory sequence, the construct-derived exon, and the construct-derived splice-donor site, in addition to all endogenous exons of the targeted gene; and (e) maintaining the homologously recombinant cell under conditions appropriate for transcription under the control of the exogenous regulatory sequence, to produce a transcript of the construct-derived exon, the targeted gene, and any sequence lying between the construct-derived exon and the targeted gene, wherein the RNA of the transcript corresponding to the construct-derived splice-donor site directs splicing to a splice-acceptor site in the transcript which corresponds to a site within the targeted gene.

7. The method of claim 6, wherein the homologously recombinant cell is, prior to introduction into the mammal, enclosed within a barrier device which permits passage of the protein from the interior of the barrier device to the exterior of the barrier device.

8. A DNA construct that alters the expression of a targeted gene in a cell when the DNA construct is homologously recombined with a target site within the chromosomal DNA of the cell, the DNA construct comprising: (a) a targeting sequence homologous to the target site; (b) an exogenous regulatory sequence; (c) an exon; and (d) an unpaired splice-donor site at the 3' end of the exon; wherein, following homologous recombination of the targeting sequence with the target site, the chromosomal DNA of the cell comprises the construct-derived exon in addition to all endogenous exons of the targeted gene, and wherein the targeted gene encodes a hormone, a cytokine, an antigen, an antibody, an enzyme, a clotting factor, a transport protein, a receptor, a regulatory protein, a structural protein, or a transcription factor.

9. A DNA construct that alters the expression of a targeted gene in a cell when the DNA construct is homologously recombined with a target site within the chromosomal DNA of the cell, the DNA construct comprising: (a) a targeting sequence homologous to the target site; (b) an exogenous regulatory sequence; (c) an exon; and (d) an unpaired splice-donor site at the 3' end of the exon; wherein, following homologous recombination of the targeting sequence with the target site, the chromosomal DNA of the cell comprises the construct-derived exon in addition to all endogenous exons of the targeted gene, and wherein the targeted gene encodes a protein selected from the group consisting of calcitonin, insulin, insulinotropin, insulin-like growth factors, parathyroid hormone, nerve growth factors, interleukins, immunoglobulins, catalytic antibodies, superoxide dismutase, tissue plasminogen activators, blood clotting factor VIII, apolipoprotein E, apolipoprotein A-I, globins, low density lipoprotein receptor, IL2 receptor, IL-2 receptor antagonists, alpha-1 antitrypsin, immune response modifiers, growth hormone, interferon, blood clotting factor IX, glucocerebrosidase, a colony stimulating factor, and erythropoietuin..

10. A DNA construct that alters the expression of a targeted gene in a cell when the DNA construct is homologously recombined with a target site within the chromosomal DNA of the cell, the DNA construct comprising: (a) a targeting sequence homologous to the target site; (b) an exogenous regulatory sequence; (c) an exon; and (d) an unpaired splice-donor site at the 3' end of the exon; wherein, following homologous recombination of the targeting sequence with the target site, the chromosomal DNA of the cell comprises the construct-derived exon in addition to all endogenous exons of the targeted gene, and wherein the exogenous regulatory sequence is a promoter, an enhancer, a scaffold-attachment region, a negative regulatory element, a transcriptional initiation site, or a regulatory protein binding site.

11. A DNA construct that alters the expression of a targeted gene in a cell when the DNA construct is homologously recombined with a target site within the chromosomal DNA of the cell, the DNA construct comprising: (a) a targeting sequence homologous to the target site; (b) an exogenous regulatory sequence; (c) an exon; (d) an unpaired splice-donor site at the 3' end of the exon; and (e) an amplifiable marker gene; wherein, following homologous recombination of the targeting sequence with the target site, the chromosomal DNA of the cell comprises the construct-derived exon in addition to all endogenous exons of the targeted gene.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.